Information Provided By: 
Fly News Breaks for June 16, 2015
PTCT
Jun 16, 2015 | 13:21 EDT
Deutsche Bank spoke with PTC Therapeutics management and said there is no new news on the current global DMD trial, DMD in Europe, and no developments in the SMA program. The firm's analyst said there is no fundamental reason for the weakness and recommends buying shares on weakness. Deutsche Bank rates PTC Therapeutics a Buy with a $115 price target on shares.
News For PTCT From the Last 2 Days
PTCT
Apr 26, 2024 | 05:57 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
Reports Q1 revenue $210M, consensus $169.7M. "We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter," said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. "We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin."
